ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1407

Resolvin D5 Modulates Th17/Treg Cell Differentiation and Suppresses Osteoclastogenesis

Hirotaka Yamada1, Jun Saegusa2, Sho Sendo3, Yo Ueda4, Takaichi Okano1, Yoshikazu Fujikawa5, Yuzuru Yamamoto6, Takumi Nagamoto1, Yoshihide Ichise1, Ikuko Naka1, Kengo Akashi7, Akira Onishi7, Masakazu Shinohara1 and Akio Morinobu7, 1Kobe University, Kobe, Japan, 2Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan, 3Kobe University, Kobe, 4Kobe UniversityRheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan, 5Kobe University, Kobe city, Japan, 6Kobe University, Kobe-city, Japan, 7Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan

Meeting: ACR Convergence 2020

Keywords: Mouse Models, RA, osteoclastogenesis, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Over the last two decades, it has become increasingly clear that resolution of acute inflammation is not a passive process, but requires active modulation. This is tightly regulated by families of novel potent bioactive lipid mediators (LM), which have been termed “specialized pro-resolving mediators” (SPMs), but little is known concerning their role in chronic inflammation, such as in rheumatoid arthritis (RA). This study was conducted to investigate whether LM are involved in the pathogenesis of RA.

Methods: We performed LM profiling on inflamed arthritic paws in a mouse model of RA by using lipid chromatography (LC) /mass spectrometry (MS) /MS-based LM metabololipidomics. CD4+ T cells from splenocytes of SKG mice were cultured on anti-CD3/ CD28 mAbs precoated plate with IL-6/TGF-β, anti-IFNγ/IL-4 and SPMs were added daily from day 0. On day 3, cells were analyzed by flow cytometry. CD4+ T cells were incubated with CFSE and RvD5 was added daily. On day 3, cell proliferation was analyzed by flow cytometry. Mouse bone marrow cells were cultured with M-CSF and RANKL and RvD5 was added daily. Tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells were defined as osteoclasts and counted under a microscope. Osteoclast differentiation markers were analyzed by quantitative RT-PCR.

Results: We found that RvE3, RvD1, RvD3, RvD5 and Maresin2 were significantly elevated in the arthritic paws. Of the elevated SPMs, levels of RvD5 correlated significantly with arthritis disease activity (Figure 1). We also found that RvD5 inhibited the differentiation of Rorγt+ Th17 cells and increased the population of Foxp3+ regulatory T (Treg) cells. In addition, RvD5 inhibited CD4+ T cell proliferation. Furthermore, RvD5 attenuated osteoclast differentiation and interfered osteoclastogenesis at the molecular level (Figure 2).

Conclusion: RvD5 is increased in the paws of arthritic mice, suppresses Th17 cell differentiation and CD4+ T cell proliferation, facilitates Treg cell differentiation, and suppresses osteoclastogenesis.


Disclosure: H. Yamada, None; J. Saegusa, None; S. Sendo, None; Y. Ueda, None; T. Okano, None; Y. Fujikawa, None; Y. Yamamoto, None; T. Nagamoto, None; Y. Ichise, None; I. Naka, None; K. Akashi, None; A. Onishi, None; M. Shinohara, None; A. Morinobu, None.

To cite this abstract in AMA style:

Yamada H, Saegusa J, Sendo S, Ueda Y, Okano T, Fujikawa Y, Yamamoto Y, Nagamoto T, Ichise Y, Naka I, Akashi K, Onishi A, Shinohara M, Morinobu A. Resolvin D5 Modulates Th17/Treg Cell Differentiation and Suppresses Osteoclastogenesis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/resolvin-d5-modulates-th17-treg-cell-differentiation-and-suppresses-osteoclastogenesis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/resolvin-d5-modulates-th17-treg-cell-differentiation-and-suppresses-osteoclastogenesis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology